What is the evidence-based management for bullous fixed‑drug eruption?

Evidence-Based Management of Bullous Fixed Drug Eruption

Immediately discontinue the suspected causative drug and initiate supportive care with local wound management; for generalized bullous fixed drug eruption (GBFDE) covering >10% body surface area, start systemic corticosteroids at 0.5-1 mg/kg/day prednisone equivalent with consideration of cyclosporine for severe or rapidly progressive cases. 1, 2

Initial Assessment and Drug Discontinuation

The cornerstone of management is immediate identification and withdrawal of the causative agent. 2, 3, 4 The most common triggers are:

• NSAIDs (48.7% of cases) - particularly concerning as many are available over-the-counter 1
• Antibiotics (30.9% of cases) 1

Key distinguishing features from Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) include:

• Rapid onset within 1-24 hours (versus weeks for SJS/TEN) 2, 3
• Minimal or absent mucosal involvement - notably, ocular mucosa is typically spared 1, 2
• Less systemic organ involvement compared to SJS/TEN 2, 3
• Recurrence at same sites with re-exposure to the drug 2, 3

However, mortality remains significant at 15.2%, particularly in elderly patients, challenging the historical perception that GBFDE is benign 1, 2

Severity Stratification and Treatment Algorithm

Localized Bullous FDE (<10% BSA)

For limited disease, topical management is appropriate:

• High-potency topical corticosteroids (clobetasol 0.05% or betamethasone) applied to affected areas 5
• Local wound care with plain petrolatum ointment and non-adherent dressings over erosions 5
• Pierce intact bullae at the base with sterile needle (bevel up) to drain fluid, but leave blister roof intact as biological dressing 6
• Monitor every 3 days for progression 5

Generalized Bullous FDE (10-30% BSA)

Hold any ongoing immunotherapy if applicable and initiate systemic treatment:

• Prednisone 0.5-1 mg/kg/day (or IV methylprednisolone 1-2 mg/kg if unable to take oral) 5
• Taper over at least 4 weeks once new lesions cease 5
• Consider hospital admission for close monitoring 5
• Dermatology consultation for steroid-sparing options and to determine if treatment escalation needed 5

Severe GBFDE (>30% BSA)

Admit immediately under dermatology supervision:

• IV methylprednisolone 1-2 mg/kg/day, convert to oral when appropriate with prolonged taper (≥4 weeks) 5
• Consider cyclosporine for rapidly progressive cases or steroid-refractory disease - emerging evidence shows rapid cessation of blistering within days 7, 8
• ICU admission may be required (19.9% of cases) 1
• Serial photography to document progression or improvement 5

Supportive Care Measures

Meticulous wound care is essential given the 15.2% mortality rate:

• Fluid and electrolyte management - monitor for imbalances, particularly in extensive disease 9, 6
• Infection prevention - daily cleansing with antimicrobial solution, aseptic dressing changes, bacterial/viral swabs if infection suspected 6
• Pain management - offer analgesia before blister care procedures; consider gabapentin for pruritus 10, 6
• Nutritional support - particularly if oral mucosa involved 6
• Thermoregulation - attention to temperature control in extensive skin loss 6

Diagnostic Workup

Obtain skin biopsy to differentiate from other bullous disorders:

• Lesional skin biopsy for routine histopathology 9
• Perilesional skin for direct immunofluorescence to exclude immunobullous disorders 9
• Laboratory evaluation: CBC with differential, liver and kidney function, electrolytes, glucose 9, 5
• Bacterial cultures from lesional skin 9

Critical Pitfalls to Avoid

Do not perform oral challenge testing to confirm the causative drug - this risks severe exacerbation or generalization; patch testing is preferred if confirmation needed 2

Do not underestimate severity based on historical literature - recent systematic review demonstrates GBFDE can be as life-threatening as SJS/TEN, particularly in elderly patients (mortality significantly associated with age, P=.01) 1, 2

Do not delay systemic corticosteroids in extensive disease - median time to resolution is 11 days with appropriate treatment 1

Failure to remove the causative agent leads to recurrence with increased inflammation, hyperpigmentation (occurs in 54.3%), and risk of progression to life-threatening GBFDE 1, 2

Expected Outcomes

• Median time to resolution: 11 days (IQR 8-17 days) with appropriate management 1
• Post-inflammatory hyperpigmentation occurs in 54.3% of cases 1
• Prognosis generally more favorable than SJS/TEN when managed appropriately, but vigilance required given significant mortality risk 1, 2